Abstract:Genetic hearing loss is a common health problem with no effective therapy currently available. DFNA15, caused by mutations of the transcription factor POU4F3, is one of the most common forms of autosomal dominant non-syndromic deafness. In this study, we established a novel mouse model of the human DFNA15 deafness, with a Pou4f3 gene mutation (Pou4f3Δ) identical to that found in a familial case of DFNA15. The Pou4f3(Δ/+) mice suffered progressive deafness in a similar manner to the DFNA15 patients. Hair cells in the Pou4f3(Δ/+) cochlea displayed significant stereociliary and mitochondrial pathologies, with apparent loss of outer hair cells. Progression of hearing and outer hair cell loss of the Pou4f3(Δ/+) mice was significantly modified by other genetic and environmental factors. Using Pou4f3(-/+) heterozygous knockout mice, we also showed that DFNA15 is likely caused by haploinsufficiency of the Pou4f3 gene. Importantly, inhibition of retinoic acid signaling by the aldehyde dehydrogenase (Aldh) and retinoic acid receptor inhibitors promoted Pou4f3 expression in the cochlear tissue and suppressed the progression of hearing loss in the mutant mice. These data demonstrate Pou4f3 haploinsufficiency as the main underlying cause of human DFNA15 deafness and highlight the therapeutic potential of Aldh inhibitors for treatment of progressive hearing loss.More than 50% of deafness cases are due to genetic defects with no treatment available. DFNA15, caused by mutations of the transcription factor POU4F3, is one of the most common types of autosomal dominant non-syndromic deafness. Here, we established a novel mouse model with the exact Pou4f3 mutation identified in human patients. The mutant mouse display similar auditory pathophysiology as human patients and exhibit multiple hair cell abnormalities. The onset and severity of hearing loss in the mouse model is highly modifiable to environmental factors, such as aging, noise exposure or genetic backgrounds. Using a new knockout mouse model, we found Pou4f3 haploinsufficiency as the underlying mechanism of human DFNA15. Importantly, we identified Aldh inhibitor as a potent small molecule for upregulation of Pou4f3 and treatment of hearing loss in the mutant mouse. The identification of Aldh inhibitor for treatment of DFNA15 deafness represents a major advance in the unmet medical need for this common form of progressive hearing loss.

A small molecule mitigates hearing loss in a mouse model of Usher syndrome III

Genetic Correction of TRMU Allele Restored the Mitochondrial Dysfunction-Induced Deficiencies in Ipscs-Derived Hair Cells of Hearing-Impaired Patients.

Clarin-2 gene supplementation durably preserves hearing in a model of progressive hearing loss

Direct Delivery of Antisense Oligonucleotides to the Middle and Inner Ear Improves Hearing and Balance in Usher Mice

PAM-flexible Adenine Base Editing Rescues Hearing Loss in a Humanized MPZL2 Mouse Model Harboring an East Asian Founder Mutation

Pathological mechanisms and candidate therapeutic approaches in the hearing loss of mice carrying human mutations

Aldh inhibitor restores auditory function in a mouse model of human deafness

Extended time frame for restoring inner ear function through gene therapy in Usher1G preclinical model

Treatment of monogenic and digenic dominant genetic hearing loss by CRISPR-Cas9 ribonucleoprotein delivery in vivo

Specific knockdown of <i>Htra2</i> by CRISPR-CasRx prevents acquired sensorineural hearing loss in mice

A base editor for the long-term restoration of auditory function in mice with recessive profound deafness

Pathological mechanisms and candidate therapeutic approaches in the hearing loss of mice carrying human MIR96 mutations

Combined AAV-mediated gene replacement therapy improves auditory function in a mouse model of human DFNB42 deafness

Elasticity and Thermal Stability are Key Determinants of Hearing Rescue by Mini-Protocadherin-15 Proteins

Hearing restoration by gene replacement therapy for a multisite-expressed gene in a mouse model of human DFNB111 deafness

Prevention of acquired sensorineural hearing loss in mice by in vivo <i>Htra2</i> gene editing

Prevention of acquired sensorineural hearing loss in mice by in vivo Htra2 gene editing

Conditional overexpression of neuritin in supporting cells (SCs) mitigates hair cell (HC) damage and induces HC regeneration in the adult mouse cochlea after drug-induced ototoxicity

In vivo base editing restores sensory transduction and transiently improves auditory function in a mouse model of recessive deafness

Rational design of a genomically humanized mouse model for dominantly-inherited hearing loss, DFNA9

The Suppression of Ubiquitin C-Terminal Hydrolase L1 Promotes the Transdifferentiation of Auditory Supporting Cells into Hair Cells by Regulating the mTOR Pathway